Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ANB032 in moderate to severe atopic dermatitis
NCT05935085Phase 2Terminated
- Sponsor
- AnaptysBio, Inc.
- Start
- Jun 2023
- Primary completion
- Oct 2024
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 7
01
Overview
A Phase 2 trial of ANB032 in atopic dermatitis (AD), sponsored by AnaptysBio, Inc.. Started Jun 2023; status: terminated.
02
Drugs
ANB032
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT05935085.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05935085.